While no trials with GLP-1 RA monotherapy have specifically assessed the impact of these drugs on hard CVD outcomes in patients with established HF (Table 1), post-hoc analyses of early studies have demonstrated significant but inconsistent reductions in HF-related hospitalizations (HHF) in individuals with obesity and type 2 diabetes [33, 34]
We help patients decide whether medications like Wegovy, Zepbound, Ozempic, Mounjaro, Oral Wegovy, or Foundayo make sense for them, and we help patients understand emerging next-generation options such as retatrutide without confusing investigational data with an available prescription
Market and Economic Implications The broader economic implications of GLP-1 drugs' success are profound
Nonetheless, further investigation is needed to elucidate the biological effect of this type of agent [186]
Retatrutide Phase 3 data (TRIUMPH program) shows the highest weight loss numbers ever recorded in pharmacotherapy trials